TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1635633

Group type: EXPERIMENTAL
Intervention: diazepam 0.3 mg/kg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: flunitrazepam 0.03 mg/kg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: promethazine 0.7 mg/kg
Number of subjects: 48

Group type: COMPARATOR
Intervention: saline
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: haematic levels of DBI
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: score scale (STAI, Y, 1‐2)
Number of subjects: 48
Study: 6438677

Group type: EXPERIMENTAL
Intervention: Marijuana cigarette (1.8% THC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 30118363

Group type: EXPERIMENTAL
Intervention: CRoC®
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: JETT™
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: SJT
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: All JTQ devices
Number of subjects: 49
Study: 30040817

Group type: EXPERIMENTAL
Intervention: Dose-dense doxorubicin-cyclophosphamide then paclitaxel
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Doxorubicin-cyclophosphamide then weekly paclitaxel
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 5-FU-epirubicin-cyclophosphamide then docetaxel
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Physician engagement, accrual rates, physician compliance, patient satisfaction with the integrated consent model
Number of subjects: 2
Study: 27260271

Group type: EXPERIMENTAL
Intervention: Probiotic mixture (Vivomixx®)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 24767604

Group type: EXPERIMENTAL
Intervention: 16-week structured home-based moderate-intensity exercise programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 0
Study: 22698765

Group type: EXPERIMENTAL
Intervention: Continuous atrial overdrive pacing (CAOP) ON
Number of subjects: 2343

Group type: COMPARATOR
Intervention: Continuous atrial overdrive pacing (CAOP) OFF
Number of subjects: 2343
Study: 20186392

Group type: EXPERIMENTAL
Intervention: High levator myorrhaphy (HLM)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Uterosacral ligament suspension (USLS)
Number of subjects: 229
Study: 18399862

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (10-week programme of exercise training)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 30
Study: 15471618

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone 400 mg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone 800 mg/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: COMPARATOR
Intervention: Unopposed estrogen
Number of subjects: 36
Study: 12089090

Group type: EXPERIMENTAL
Intervention: Intensive orthoptic screening at 8, 12, 18, 25, 31, and 37 months
Number of subjects: 3490

Group type: COMPARATOR
Intervention: Control group (orthoptic screening at 37 months only)
Number of subjects: 3490
Study: 10334441

Group type: EXPERIMENTAL
Intervention: Laser lead extraction with the excimer sheath
Number of subjects: 301

Group type: COMPARATOR
Intervention: Nonlaser lead extraction
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Laser lead extraction
Number of subjects: 301
Study: 8951189

Group type: EXPERIMENTAL
Intervention: (+/‐)‐sotalol single doses of 40, 80 and 160 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (+/‐)‐sotalol multiple doses of 80 mg twice daily for 7 consecutive days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (+/‐)‐sotalol single doses of 80 and 160 mg
Number of subjects: 0
Study: 1956099

Group type: EXPERIMENTAL
Intervention: 21 mg transdermal nicotine
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: 14 mg transdermal nicotine
Number of subjects: 935

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: All transdermal nicotine doses
Number of subjects: 935
Study: 30009410

Group type: EXPERIMENTAL
Intervention: POMONA-ESP project methodology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: POMONA-ESP project
Number of subjects: 0
Study: 29229440

Group type: EXPERIMENTAL
Intervention: Doxycycline PEP (200 mg single oral dose within 24 hours after sex)
Number of subjects: 232

Group type: COMPARATOR
Intervention: No PEP
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Doxycycline PEP
Number of subjects: 232

Group type: COMPARATOR
Intervention: Doxycycline PEP and No PEP
Number of subjects: 232
Study: 27564444

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) program during hearing aid fitting
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard Practice (SP)
Number of subjects: 50
Study: 25098218

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 22503337

Group type: EXPERIMENTAL
Intervention: Placebo manipulation (open or hidden administrations of lidocaine)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Placebo manipulation
Number of subjects: 19
Study: 20683750

Group type: EXPERIMENTAL
Intervention: Pudendal nerve block
Number of subjects: 120

Group type: COMPARATOR
Intervention: Local anesthesia
Number of subjects: 120
Study: 17992062

Group type: EXPERIMENTAL
Intervention: PABM-intervention (50 minutes of physical activity twice a week + 50 minutes of behavior modification once a week)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Behavior modification only intervention (50 minutes of instruction for modifying lifestyle habits once a week)
Number of subjects: 32
Study: 15871112

Group type: EXPERIMENTAL
Intervention: HPV acquisition in younger women
Number of subjects: 7237

Group type: EXPERIMENTAL
Intervention: HPV persistence in older women
Number of subjects: 7237

Group type: EXPERIMENTAL
Intervention: Overall HPV trends
Number of subjects: 7237
Study: 11885548

Group type: EXPERIMENTAL
Intervention: Full vegetable fat milk (FVF) (3.5 g fat/dL; 100% vegetable fat from palm-, coconut- and soybean oil)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Partially vegetable fat milk (PVF) (3.5 g fat/dL; 50% vegetable fat from rapeseed oil, 50% milk fat)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard-fat milk (SF) (3.5 g cow's milk fat/dL)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Low-fat milk (LF) (1.0 g cow's milk fat/dL)
Number of subjects: 37
Study: 11725682

Group type: EXPERIMENTAL
Intervention: Syntac Sprint/Tetric Ceram
Number of subjects: 33

Group type: COMPARATOR
Intervention: Syntac Classic/Tetric
Number of subjects: 33
Study: 7497825

Group type: EXPERIMENTAL
Intervention: Pain-denying feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misleading information about actions of the pediatrician and assistant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonmisleading information about actions of the pediatrician and assistant
Number of subjects: 0
Study: 2197158

Group type: EXPERIMENTAL
Intervention: Dilevalol (200 mg once daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dilevalol (400 mg once daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Captopril (50 mg twice daily)
Number of subjects: 30
Study: 6791204

Group type: EXPERIMENTAL
Intervention: Naltrexone 200 mg per day for 1 week
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30346191

Group type: EXPERIMENTAL
Intervention: Distress task condition
Number of subjects: 126

Group type: COMPARATOR
Intervention: Neutral (reading) task condition
Number of subjects: 126
Study: 29303128

Group type: EXPERIMENTAL
Intervention: Transbuccal group (Group A) fixed with 7 mm long self‐tapping 2.0 mm titanium screws at 85° to the reference line
Number of subjects: 20

Group type: COMPARATOR
Intervention: Transoral group (Group B) fixed with 7 mm long self‐tapping 2.0 mm titanium screws at 15° to the reference line
Number of subjects: 20
Study: 26098427

Group type: EXPERIMENTAL
Intervention: Vitamin B12 and Folic Acid
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Vitamin B12 alone
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study: 25638996

Group type: EXPERIMENTAL
Intervention: Sutured extraction wound (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Absorbable gelatin sponges without suturing (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No gelatin sponge or suturing (Group C)
Number of subjects: 90
Study: 23098014

Group type: EXPERIMENTAL
Intervention: Clinical simulation intervention group participating in two simulated pediatric palliative care scenarios
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 19923506

Group type: EXPERIMENTAL
Intervention: Systemic lidocaine infusion
Number of subjects: 67

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 67
Study: 16897236

Group type: EXPERIMENTAL
Intervention: Ulinastatin (6000 units x kg(‐1) infusion started 1 h after surgery)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no protease inhibitors infused)
Number of subjects: 30
Study: 13129862

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation treatment
Number of subjects: 214
Study: 11075308

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) administered by dry-powder inhaler (DPI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) administered by metered-dose inhaler with an alternate propellant (MDI-AP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) administered by intravenous (i.v.) route
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) administered by DPI (separate study with tritiated MF)
Number of subjects: 30
Study: 8898422

Group type: EXPERIMENTAL
Intervention: Screening group (flexible sigmoidoscopic screening)
Number of subjects: 799

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 799

Group type: COMPARATOR
Intervention: Non-attendees for screening examination
Number of subjects: 799
Study: 1892032

Group type: EXPERIMENTAL
Intervention: Barium sulfate (600-900 ml orally and 400 ml rectally)
Number of subjects: 10
Study: 6308933

Group type: EXPERIMENTAL
Intervention: Maximized metabolic control (group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard control (group A)
Number of subjects: 0
Study: 30662004

Group type: EXPERIMENTAL
Intervention: Kefir (400 mL/day for 4 weeks)
Number of subjects: 45
Study: 28797450

Group type: EXPERIMENTAL
Intervention: Early tube feeding prior to treatment
Number of subjects: 125

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 125
Study: 25836351

Group type: EXPERIMENTAL
Intervention: 30-month treatment with fluticasone and salmeterol (500/50 μg bid)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 30-month treatment with fluticasone (500 μg bid)
Number of subjects: 114
Study: 23380979

Group type: EXPERIMENTAL
Intervention: Visual rehabilitation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Magnifying visual aids (Control)
Number of subjects: 20
Study: 21935686

Group type: EXPERIMENTAL
Intervention: Rocuronium administered at 0.7‐1.0 mg/kg for tracheal intubation, with repeated bolus administration (10 mg) or continuous infusion (15‐25 mg/h)
Number of subjects: 134
Study: 18077189

Group type: EXPERIMENTAL
Intervention: Tidal irrigation (TI) using a 3.2mm arthroscope under local anaesthesia
Number of subjects: 150

Group type: COMPARATOR
Intervention: Corticosteroid injection (CSI) of 40 mg triamcinolone acetonide and 1% lidocaine
Number of subjects: 150
Study: 16595218

Group type: EXPERIMENTAL
Intervention: Luteinizing hormone (LH) surge group
Number of subjects: 150

Group type: COMPARATOR
Intervention: Follicle monitoring/human chorionic gonadotropin (hCG) group
Number of subjects: 150
Study: 14973802

Group type: EXPERIMENTAL
Intervention: Early extubation (2 hours after surgery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Late extubation (6 hours after surgery)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups received a bolus of ketobemidone and continuous infusion
Number of subjects: 60
Study: 11212161

Group type: EXPERIMENTAL
Intervention: 5 mg alendronate (ALN)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: 10 mg alendronate (ALN)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: 2.5/10 mg alendronate (ALN)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Any dose of alendronate (ALN)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: 5 mg and 10 mg alendronate (ALN)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN)
Number of subjects: 208
Study: 9458995

Group type: EXPERIMENTAL
Intervention: Behavioral and environmental interventions based on Piaget's cognitive developmental stages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 8172505

Group type: EXPERIMENTAL
Intervention: Regional Intravenous Ismelin blocks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Hydroxyl radical scavenger, dimethylsulfoxide (DMSO)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (elective hand-surgery patients)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Dystrophy patients
Number of subjects: 26
Study: 2450479

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 11
Study: 30222120

Group type: EXPERIMENTAL
Intervention: BioMime sirolimus‐eluting stent (SES)
Number of subjects: 256

Group type: COMPARATOR
Intervention: XIENCE everolimus‐eluting stent (EES)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: BioMime SES
Number of subjects: 256

Group type: COMPARATOR
Intervention: XIENCE EES
Number of subjects: 256
Study: 26279490

Group type: EXPERIMENTAL
Intervention: McGrath video laryngoscope
Number of subjects: 35
Study: 25428566

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy with wrist orthosis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paraffin bath therapy with wrist orthosis
Number of subjects: 60
Study: 23567980

Group type: EXPERIMENTAL
Intervention: Intervention group (8 departments; N = 171 workers)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Control group (7 departments; N = 122 workers)
Number of subjects: 297
Study: 20736470

Group type: EXPERIMENTAL
Intervention: Elective IABP insertion before PCI
Number of subjects: 301

Group type: COMPARATOR
Intervention: No planned IABP
Number of subjects: 301
Study: 19013107

Group type: EXPERIMENTAL
Intervention: Vinorelbine (25 mg/m²) plus gemcitabine (1000 mg/m²) followed by docetaxel (60 mg/m²)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Paclitaxel (225 mg/m²) plus carboplatin (AUC=6)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Vinorelbine plus gemcitabine followed by docetaxel
Number of subjects: 401

Group type: COMPARATOR
Intervention: Paclitaxel plus carboplatin
Number of subjects: 401
Study: 16377253

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 37
Study: 12709263

Group type: EXPERIMENTAL
Intervention: Satisfactory BP control (group I)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Uncontrolled clinic BP (group II)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Refractory hypertension (group III)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Non-dipping status
Number of subjects: 229
Study: 10846775

Group type: EXPERIMENTAL
Intervention: MCA PSV > 1 SD
Number of subjects: 196

Group type: COMPARATOR
Intervention: MCA PSV
Number of subjects: 196
Study: 9096989

Group type: EXPERIMENTAL
Intervention: Simvastatin, 20 mg daily, titrated up to 40 mg daily
Number of subjects: 202
Study: 8253923

Group type: EXPERIMENTAL
Intervention: Org 31338 [FSH/LH 3:1]
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metrodin (purified FSH)
Number of subjects: 20
Study: 3330028

Group type: EXPERIMENTAL
Intervention: Slow-release nifedipine 20 mg b.d.
Number of subjects: 94

Group type: COMPARATOR
Intervention: Cyclopenthiazide 0.25 mg with 8.1 mmol potassium daily
Number of subjects: 94
Study: 29092786

Group type: EXPERIMENTAL
Intervention: AR101
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 27175282

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No-exercise (usual care) control group
Number of subjects: 15
Study: 23825160

Group type: EXPERIMENTAL
Intervention: Sonicare FlexCare electric brush with filled resin sealant (ProSeal)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Manual (elmex interX short head) plus interdental (Curaprox CPS 15) brush with filled resin sealant (ProSeal)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Manual brush only with filled resin sealant (ProSeal)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Manual brush only without sealant
Number of subjects: 118
Study: 22682391

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (8 sessions over a 4-week period)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine follow-up care (Control group)
Number of subjects: 80
Study: 19545680

Group type: EXPERIMENTAL
Intervention: Cordyceps sinensis (CS) 1.0 g 3 times a day
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group (standard immunosuppressive regimen)
Number of subjects: 202
Study: 17304127

Group type: EXPERIMENTAL
Intervention: Bilateral instrumentation (Group 1)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Unilateral instrumentation (Group 2)
Number of subjects: 82
Study: 15087307

Group type: EXPERIMENTAL
Intervention: Hydrogenated fat diet
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Saturated fat diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Unsaturated fat diet
Number of subjects: 8
Study: 11579708

Group type: EXPERIMENTAL
Intervention: Iloprost (2 ng/kg/min for 5 consecutive days over 8 hours/day, then 8 hours on one day every 6 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Nifedipine (40 mg/day orally)
Number of subjects: 46
Study: 9676145

Group type: EXPERIMENTAL
Intervention: Fibre-supplemented enteral formula (FSF)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fibre-free formula (FFF)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 8087503

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2569322

Group type: EXPERIMENTAL
Intervention: CGP 17/582 (100 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 778306

Group type: EXPERIMENTAL
Intervention: Ribavirin (600 mg/day in three divided doses)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 15
Study: 30496706

Group type: EXPERIMENTAL
Intervention: HYPO (hypohydration)
Number of subjects: 16

Group type: COMPARATOR
Intervention: RE (rehydration)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HYPO
Number of subjects: 16
Study: 28877715

Group type: EXPERIMENTAL
Intervention: Oral Pirfenidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26194933

Group type: EXPERIMENTAL
Intervention: Automated control of FiO2
Number of subjects: 27

Group type: COMPARATOR
Intervention: Manual control of FiO2
Number of subjects: 27
Study: 23440694

Group type: EXPERIMENTAL
Intervention: IVIG treatment
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Pre-IVIG cytokine levels
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Post-IVIG cytokine levels
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: IL-10 level >8 pg/ml (pre-IVIG)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: TNFα level <2 pg/ml (pre-IVIG)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: IL-6 level >10 pg/ml (post-IVIG)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: IL-10 level >6 pg/ml (post-IVIG)
Number of subjects: 143
Study: 21146468

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (NMDA receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19463081

Group type: EXPERIMENTAL
Intervention: Physiotherapist-supervised exercises in addition to conventional intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional intervention (control group)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Self-reported recovery
Number of subjects: 102
Study: 22297150

Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride (.5 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 15900286

Group type: EXPERIMENTAL
Intervention: 600 mg gemfibrozil
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg itraconazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: gemfibrozil and itraconazole combination
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 12821221

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72
Study: 10535238

Group type: EXPERIMENTAL
Intervention: Parent-training program
Number of subjects: 238
Study: 7594122

Group type: EXPERIMENTAL
Intervention: Exercise plus dietary intervention (n = 15)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Exercise only (n = 17)
Number of subjects: 32
Study: 2187175

Group type: EXPERIMENTAL
Intervention: Nebulized metaproterenol sulfate 5% inhalant solution at a dose of 0.01 mL/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nebulized metaproterenol sulfate 5% inhalant solution at a dose of 0.02 mL/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 30
Study: 7023676

Group type: EXPERIMENTAL
Intervention: Five-day treatment with cephradine capsules, 500 mg BID
Number of subjects: 71

Group type: COMPARATOR
Intervention: Ten-day treatment with cephradine capsules, 500 mg BID
Number of subjects: 71
Study: 29191135

Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 360

Group type: COMPARATOR
Intervention: Neutral message
Number of subjects: 360

Group type: COMPARATOR
Intervention: Loss-framed message
Number of subjects: 360